Trevarx Biomedical, Inc
Trevarx develops small molecule radiopharmaceutical platforms focusing on oncology. Its first platform is a PARP inhibitor (PARPi) analogue with an α-emitting radioligand therapy [211At]PTT (currently in pre-clinical stage) with published proof of concept in neuroblastoma seeking additional indications in adult PARP-1 tumors. Trevarx's PARPi platform has a companion PET biomarker [18F]FTT (entering Phase 2 Multi-Center trials in breast cancer in Spring 2022, led by MD Anderson Cancer Center).
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
0
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Trevarx Biomedical, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Sign up to unlock all 1 contacts at Trevarx Biomedical, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Trevarx Biomedical, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.